OSLO, Norway, Feb. 28, 2022 /PRNewswire/ -- Targovax
ASA (OSE: TRVX) a clinical-stage immuno-oncology company
developing immune activators to target hard-to-treat solid tumors,
today announces that it has appointed Dr. Lubor Gaal as Chief Financial Officer (CFO),
effective as of 7 March 2022.
Dr. Lubor Gaal is a seasoned
industry executive with 25 years of experience working in large
pharmaceutical and biotechnology companies in Europe and the USA. Most recently, he served as Managing
Director and Head of Europe at
Locust Walk, a global life science boutique investment bank. At
Locust Walk, Dr. Gaal was responsible for overseeing all European
strategic transactions, including financings, M&A and
licensing. Before Locust Walk, he was Head of External Innovation
and Licensing and a member of the R&D Management Committee at
Almirall and Head of Europe Search and Evaluation for oncology at
Bristol-Myers Squibb. Prior to that, Dr. Gaal held executive
management positions at Neuro3d and Vectron Therapeutics, and
global business development roles in Bayer. Dr. Gaal has a Ph.D. in
molecular and cell biology from the University
of California at Berkeley, USA.
In Targovax, Dr. Gaal's core responsibilities will be to oversee
all financial, investor relations and business development
activities, as well as playing an integral role in defining and
executing the corporate strategy.
Dr. Erik Digman Wiklund, CEO,
commented: "We are extremely pleased to have attracted an
individual of Lubor's caliber to Targovax. Lubor has deep
experience in business development, commercial and advisory roles
in both big pharma and development-stage biotech companies, and,
importantly, brings access to his broad, international industry
network into Targovax. With the addition of Lubor, we have now
established a world-class management team ready to execute on our
clinical program, pipeline development and corporate strategy."
Dr. Lubor Gaal added:
"Targovax has built a strong clinical portfolio, and I am very
excited to join the team to help bring their innovative cancer
immunotherapy pipeline to fruition. In my opinion, the
class-leading clinical stage ONCOS-102 asset combined with the
emerging circular RNA program puts Targovax in a unique position
for success. I have previously had the pleasure to work with
Targovax in an advisory role and experienced the quality and
strength of both the science and the people, and now I really look
forward to become a member of the organization."
Dr. Gaal will join Targovax as CFO on 7
March 2022.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa-strengthens-management-with-lubor-gaal-as-chief-financial-officer,c3515496
